ACR Convergence 2025 – MRT-6160, a VAV1-directed molecular glue degrader, attenuates T and B cell effector functions and inhibits disease progression in a spontaneous[...]

Monte Rosa Therapeutics Inc. published this content on October 26, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2025 at 15:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]